A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer
The Oncologist · 2026
DOI: 10.1093/oncolo/oyag232 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2026. Verfasst von Alexa F Viniotis und 20 weiteren Autor:innen. Beteiligte Einrichtung: HonorHealth Research Institute - Oncology Department, Scottsdale, AZ 85258, United States. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Pancreatic Neoplasms, Ergocalciferols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HonorHealth Foundation, Seena Magowitz Foundation, NCI NIH HHS.
Abstract (Originalsprache)
Background
For patients with untreated pancreatic ductal adenocarcinoma (PDAC), chemotherapy before surgery (“neoadjuvant therapy”) has shown benefit in reducing recurrence and prolonging survival. Targeting the vitamin D receptor (VDR) with analogs such as paricalcitol may improve chemotherapy effectiveness. This study evaluated the efficacy and safety of neoadjuvant albumin-bound paclitaxel (nab-paclitaxel) plus cisplatin plus gemcitabine (NABPLAGEM) plus paricalcitol (NCT03138720).
Methods
Participants were ≥18 years, had stage I-III PDAC without prior chemotherapy or radiation, Karnofsky Performance Status ≥70, and elevated CA 19-9. Study treatment included nab-paclitaxel (125 mg/m2), cisplatin (25 mg/m2), gemcitabine (1000 mg/m2), and paricalcitol (25 mcg) on days 1 and 8 of a 21-day cycle for up to 6 months. The primary outcome was CA 19-9 normalization. Secondary outcomes included margin-negative resection (R0), pathologic complete response (pCR), radiologic response, safety, and survival. Microbiome was analyzed as an exploratory outcome.
Results
Thirty-two participants were enrolled with median age 69.4 years, 56.2% male, and 93.8% white. Patients had resectable (cohort A, n = 10) and borderline resectable/locally advanced (cohort B, n = 22) tumors. CA 19-9 normalization occurred in 14 patients (43.8%). Two patients (6.2%) achieved pCR, and 19 (59.4%) achieved R0. Complete or partial radiologic response occurred in 39.3% of patients. Adverse events included grade 3-4 anemia (43.8%) and thrombocytopenia (59.4%). Median (95% CI) overall survival was 43.2 (7.5–upper bound not achieved) and 18.4 (10.9-41.2) months for cohorts A and B, respectively.
Conclusion
Neoadjuvant NABPLAGEM plus paricalcitol demonstrated a high CA 19-9 normalization rate and was fairly well tolerated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HonorHealth Research Institute - Oncology Department, Scottsdale, AZ 85258, United States.
- University of Arizona Cancer Center - Biostatistics Department, Tucson, AZ 85704, United States.
- Translational Genomics Research Institute North - Immunology and Microbiome Division, Flagstaff, AZ 86005, United States.
- Snyder Patient Advocacy and Navigation, Cave Creek, AZ 85331, United States.
- HonorHealth Scottsdale Shea Medical Center - Interventional Gastroenterology, Scottsdale, AZ 85258, United States.
- Arizona Premier Surgery - General Surgery, Scottsdale, AZ 85258, United States.
ORCID-Profile: Alexa F Viniotis, Gayle S Jameson, Betsy C Wertheim, Denise J Roe, Keehoon Lee, Frank Y Tsai, Michael S Gordon, Sunil Sharma, Jacqueline M Garrick, Syed Rahmanuddin, Ronald M Evans, Michael Downes, Daniel D Von Hoff, Erkut H Borazanci
Förderung
- HonorHealth Foundation
- Seena Magowitz Foundation
- NCI NIH HHS
- Translational Genomics Research Institute National Advisory Council, Michael and Mary Ellen Francis
Zitieren
APA
Viniotis, A. F., Jameson, G. S., Wertheim, B. C., Roe, D. J., Lee, K., Tsai, F. Y., Gordon, M. S., Sharma, S., Guarnieri, C. M., Snyder, C. E., Thosani, A. J., Amini, A., Sckolnik, S. E., Garrick, J. M., Korn, R. L., Rahmanuddin, S., Evans, R. M., Downes, M., Truitt, M., …, & Borazanci, E. H. (2026). A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyag232
Vancouver
Viniotis AF, Jameson GS, Wertheim BC, Roe DJ, Lee K, Tsai FY, et al. A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer. The Oncologist. 2026. doi:10.1093/oncolo/oyag232
BibTeX
@article{Viniotis2026,
author = {Viniotis, Alexa F and Jameson, Gayle S and Wertheim, Betsy C and Roe, Denise J and Lee, Keehoon and Tsai, Frank Y and Gordon, Michael S and Sharma, Sunil and Guarnieri, Carol M and Snyder, Courtney E and Thosani, Amar J and Amini, Albert and Sckolnik, Steven E and Garrick, Jacqueline M and Korn, Ronald L and Rahmanuddin, Syed and Evans, Ronald M and Downes, Michael and Truitt, Morgan and Von Hoff, Daniel D and Borazanci, Erkut H},
title = {A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM), and paricalcitol as neoadjuvant therapy in pancreatic cancer},
journal = {The Oncologist},
year = {2026},
doi = {10.1093/oncolo/oyag232}
}
EUVIMED